Greenphire Partners with Lyft to Support Clinical Trial Patient Retention and Access
KING OF PRUSSIA, Pa., June 19, 2018 /PRNewswire/ -- Greenphire, the global leader in financial software for clinical trials, today announced it has partnered with Lyft, to deliver a seamless experience for site coordinators to book a ride and execute a reimbursement or stipend for clinical trial participants within its industry-leading ClinCard solution. With this integration, the clinical research community will have one seamless application to eliminate both the financial and logistical hurdles that impact clinical trial retention.
"Expense management and ground transportation are critical to participant retention. However, patient and site needs are not equal. That is why we have designed the only application that allows a study coordinator to order a car, reimburse for a ride, and provide a stipend all within one software," said Jim Murphy, CEO, Greenphire.
Greenphire's ClinCard is the industry standard in participant payment automation, facilitating more than six million reimbursements to over one million clinical trial participants around the world. The new offering is the only solution that brings both ride and payment automation within one central application, delivering a better experience for both sites and participants.
"Lyft is committed to improving accessibility for patients in need of better transportation options," said Gyre Renwick, Vice President of Lyft Business. "This opportunity to extend our services with Greenphire allows us to work together to create the best experience for clinical trial participants and help to eliminate any complications for patients getting to and from their appointments."
Centralizing the participant retention budget within ClinCard eliminates siloes and optimizes financial visibility and predictability for sponsors. It also allows sponsors to make clinical trial participation easier for patients, without adding an administrative burden for site coordinators.
About Greenphire
Greenphire is the global leader in clinical trial payment software. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more at www.greenphire.com.
Media Contact:
Kathleen Fusco
(267) 828-4862
Kathleen.Fusco@greenphire.com
SOURCE Greenphire
Related Links
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
